By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
An artificial pancreas is a three-part device that mimics how a healthy pancreas regulates blood glucose, also known as blood sugar, in the body. People with type 1 diabetes are typically helped by a prosthetic pancreas.
The pancreas does not generate insulin when a person has type 1 diabetes. People with type 1 diabetes manage their blood sugar levels by monitoring them and administering insulin several times per day via injection or insulin infusion device.
The Global Smart Artificial Pancreas market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The artificial pancreas device will be launched in Europe by Abbott’s diabetes team-up with Ypsomed and CamDiab.
These blood sugar readings will be sent to an intelligent insulin pump from Ypsomed and a mobile app created by CamDiab, a spinoff company from the University of Cambridge that recently showed how its artificial pancreas software could help manage Type 1 diabetes in toddlers and young children.
The CamAPS FX, which is already approved in Europe, is a highly adaptive algorithm that when combined with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lessening the burden of managing a condition that is relentlessly unpredictable day and night.
The CamAPS FX self-learning app is a hybrid, closed-loop system that works with users as young as one year old and operates on an Android smartphone.
CamDiab has been working with Ypsomed to connect the software with its mylife YpsoPump system while depending on information from Dexcom’s G6 continuous glucose monitor to adjust insulin doses and assist in preventing blood sugar levels from falling too low or rising too high.
Results from a randomised clinical study were presented by CamDiab, demonstrating that participants spent an extra two hours per day on average with stable levels and that more than 70% of children were able to go 24 hours without their glucose readings leaving a healthy range.
